Clinical trial · Observational
Non-interventional Study of Cabozantinib in Adults With Advanced Renal Cell Carcinoma
Prospective Non Interventional Study of Cabozantinib Tablets in Adults With Advanced Renal Cell Carcinoma Following Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The objective of this study is to understand the utilization of cabozantinib in subjects with advanced renal cell carcinoma (RCC) following prior VEGF-targeted therapy in real life settings in terms of dose modifications due to adverse events (AEs) when used as a second line therapy or third and later line therapy. Other patterns of use of cabozantinib will also be described.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Renal Cell Carcinoma | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Data collection | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Second line therapy
- description
- Data collection
- interventionNames
- Other: Data collection
- label
- Third and later line therapy
- description
- Data collection
- interventionNames
- Other: Data collection
Primary outcomes (1)
- measure
- The proportion of subjects with dose modifications due to AEs
- timeFrame
- 12 months
Secondary outcomes (15)
- measure
- Reason for cabozantinib dose modification (any modification, reduction, temporary interruption or discontinuation)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥18 years old * Has a diagnosis of advanced RCC * Has received at least one prior VEGF-targeted therapy * For whom the treating physician has decided to start treatment with cabozantinib tablets prior to inclusion * No previous exposure to cabozantinib prior to inclusion * Not concurrently involved in an interventional study * Consents to participate in this noninterventional study Exclusion Criteria: * There are no exclusion criteria for this study.
References
Publications (0)
Data not yet available